Lung Cancer Clinical Trial
Official title:
Curative Treatment Modalities of Early Stages Non-Small Cell Lung Cancer: Effect on Patient Reported Outcomes of Video Assisted Thoracoscopic (VATS) Resection and Stereotactic Ablative Body Radiotherapy (SABR)
This study will monitor the effect on patients reported outcomes (PROMs) of VATS resection
and SABR for NSCLC delivered at the Leeds Cancer Centre The investigator will support with
this information the Shared Decision Making (SDM) process.
300 consecutive patients will be followed up from prior the treatment to 12 months
afterwards, administering multiple questionnaires (EORTC QLQ C-30 and LC-13, PSQ-18, Decision
Self-Efficacy Scale) by a remote web-based system.
Deliverable:
1. Differences after VATS resections or SABR in terms of physical and psychological
symptoms, quality of life and satisfaction
2. Patient perspectives of the Shared Decision Making Process.
1. Methods
Aim and Objectives
This study aims to describe the trajectory of lung cancer patients HRQoL, symptoms and
functions following VATS or SABR treatment for Stage I-II NSCLC and to determine the
feasibility and patient acceptability of online self-reporting of PROMs.
Specific objectives of the study include:
- To compare changes before and after treatment of patient reported outcomes (HRQOL
and Patient Satisfaction) after VATS lung resections or SABR in early stage lung
cancer patients.
- To correlate clinical outcomes (complications and AEs) with Quality of Life in
order to find objective predictors of major decline in patient reported outcomes.
- To identify specific factors, which have influenced the personal choice between the
treatments (Decision Self-Efficacy Scale)
- Establish recruitment and attrition rates and adherence to PROMs reporting during
the study
- To describe patient choice of electronic vs paper questionnaires
- To explore implementation issues through patient and staff interview.
2. Design
This is an observational prospective longitudinal study with repeated measures (PROMs),
employing a convenience sample of consecutive patients planned to have VATS resections or
SABR for stages I-II of NSCLC. Outcomes measures will be collected prior to treatment and
1,3,6,12 months afterwards, administering the questionnaires by the remote web-based system.
Paper administration will be offered to patients without Internet access.
Sample size considerations
Last year 100 pre-surgical quality of life questionnaires have been collected in 5 months
from outpatients' clinic at Leeds Cancer Centre (LCC). For longitudinal studies involving
regular PROMs, the investigators typically see 70% consent rate and 30-35% attrition over 3
months24. Therefore the investigators expectations are to be able to recruit 200 VATS and 50
SABR patients recruiting over 12 months with 12 months of follow-up.
In order to detect a minimum difference of 10% from the baseline value and standard deviation
of the EORTC QLQ-C30 Global Health Scale scale (as measured in our historical cohort of 115
anatomic lung resections), with a alfa level of 0.05 and statistical power of 90%, a sample
size of 115 patients in the surgical arm was estimated.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|